Introduction
Over the past decade, the technique of gene targeting using homologous recombination in embryonic stem cells has become accessible to most laboratories. The ability to generate animals bearing precise and pre-planned alterations in their genome has dramatically expanded the scope of biomedical investigation. For now, the mouse is the only mammalian species in which gene targeting can be accomplished, because germ line-competent embryonic stem (ES) cells have so far only been isolated from mice. In disciplines such as immunology, a long experience with the mouse as an experimental model facilitated the rapid application and widespread use of gene targeting. 1 In contrast, the small body size of the mouse and lack of experience in using the mouse for whole animal experiments created some impediments to implementing this technology in the physiological sciences. However, many of the technical hurdles for performing physiological experiments in mice have been overcome and such studies have now become almost routine. Accordingly, over the past five years, gene targeting approaches have been applied to a wide range of physiological systems including the reninangiotensin-aldosterone system (RAAS).
The key role of the RAAS in the regulation of blood pressure (BP) and cardiovascular functions has long been recognised. 2 Accordingly, the physiology, pharmacology, biochemistry, and molecular biology of this system have been intensely investigated. Gene targeting studies of the RAAS have, in some cases, provided confirmation of previous notions regarding RAAS functions. In other cases, the results have been surprising or have suggested novel physiological roles for RAAS genes. This paper reviews studies of mice in which the genes encoding the angiotensin II type 1 (AT 1 ) receptors have been disrupted by gene targeting, emphasising the unique perspectives provided by this molecular genetic approach.
Angiotensin receptors
The biological actions of angiotensin II are mediated by cell surface receptors that belong to the family of G protein-coupled receptors. 3 There are two pharmacological classes of angiotensin receptors, type 1 (AT 1 ) and type 2 (AT 2 ), that were originally identified based on their differential affinities for various non-peptide antagonists.AT 1 -receptors from several species have been cloned, 4,5 and two subtypes, designated AT 1A and AT 1B , have been identified in rat 6 and mouse. 7 A single report has suggested that AT 1B -receptors might also exist in man, 8 but this has not been confirmed in the unpublished work of several independent groups. The consensus view is that there is no human counterpart to the murine AT 1B -receptor. The rodent AT 1 -receptors are products of separate genes (Agtr1a and Agtr1b) 9 and they share substantial DNA sequence homology. 6, 7 AT 1A -receptors predominate in most organs, except the adrenal and pituitary glands, where AT 1B expression may be more prominent. [10] [11] [12] The pharmacological profiles of the AT 1A -and AT 1B -receptors are virtually identical, 12 and thus it has been difficult to discriminate their in vivo functions using currently available ligands. Experiments using gene targeting have provided the first insights into the distinct functions of the two murine AT 1 -receptor genes.
The development of specific, non-peptide angiotensin II receptor antagonists (AIIAs) was a major advance in the RAAS field. Clinical and pharmacological studies using these agents suggested that most of the biologically important functions of the RAAS are mediated by AT 1 -receptors. 3 As will be discussed below, this view has been confirmed in studies with knockout mice. The physiological functions of the AT 2 -receptor are less clearly defined. However, recent studies have suggested that AT 2 -receptors may function to oppose or modulate the actions of AT 1 -receptors with respect to BP and cellular proliferation. 13, 14 Our studies in mice lacking AT 1 -receptors are consistent with this notion. 15
Role of AT 1 -receptors in development
In their initial phase, all gene targeting experiments become experiments in developmental biology, where the effects of the complete absence of a specific gene product on foetal development and survival are determined. A series of studies had suggested an important role for the RAAS and for AT 1receptors in foetal development. For example, expression of RAAS genes is enhanced in a number of foetal tissues 16 and angiotensin receptors are expressed in a tightly regulated programme during renal morphogenesis. 17 Because administration of ACE-I or AT 1 -receptor antagonists causes widespread structural and growth abnormalities in the kidney, [18] [19] [20] this enhanced expression of RAAS genes seemed to predict critical functions related to renal growth and development. To a limited extent, the initial reports describing the characteristics of mice with targeted inactivation of the angiotensinogen (Agt) or angiotensin-converting enzyme (ACE) gene bore out these predictions. 21, 22 For example, only a small percentage of angiotensinogen deficient (Agt -/-) mice survive to weaning, although the expected number of viable Agt -/-mice are present at birth and the histomorphology of the major organ systems, including the kidney, is normal in newborn Agt -/-mice. Those that live to adulthood develop distinctive abnormalities of their kidneys, including atrophy of the renal papilla and thickening of small arteries and arterioles. 21, 22 These vascular abnormalities are seen in the renal circulation, but not in any other vascular bed 23 and they are characterised by medial hypertrophy and/or hyperplasia; interlobular arterioles are most prominently affected. This pathological lesion most closely resembles the vascular lesions seen in hypertensive nephrosclerosis.Yet, it occurs in animals with BPs that are 20 mmHg below normal.
Despite its putative role as the major AT 1receptor isoform, disruption of the AT 1A -receptor gene (Agtr1a) in mice did not cause severe postnatal mortality or the structural abnormalities seen in kidneys of Agt -/-or Ace -/-mice. [24] [25] [26] The renal morphology of Agtr1a -/-mice with mixed genetic backgrounds was essentially preserved, with the exception of juxtaglomerular apparatus hypertrophy [24] [25] [26] and occasional mesangial hypertrophy. 27 Likewise, mice lacking AT 2 - 28, 29 or AT 1B - 15, 30 receptors also survived in normal numbers and their renal morphology was normal.
The failure to reproduce the Agt -/-phenotype by individual disruption of the known angiotensin receptor genes raised the possibility that there might be a novel, unidentified angiotensin receptor that functions to regulate vascular growth and integrity. Alternatively, the combined absence of signalling through at least two of the known receptor subtypes might be required to reproduce the phenotype associated with the complete absence of angiotensin II (Ang II). As the genes encoding the individual AT 1 -receptors (Agtr1a and Agtr1b) are located on separate chromosomes, 9 the targetted mutations of these two genes could be combined through simple breeding. Unlike mice lacking AT 1A -or AT 1B -receptors alone, the phenotype of the AT 1A /AT 1B 'double knockout' mice was virtually identical to the Agt -/-or Ace -/mice. 15, 31 These animals have significantly reduced postnatal survival, very low BPs, and, as shown in Figure 1 , they manifest prominent renal arteriolar thickening, and marked atrophy of the renal papilla. 15, 31 These studies demonstrated that both AT 1receptor isoforms contribute to the regulation of vascular structures in the kidney and that the absence of both AT 1 -receptor isoforms was required to produce this phenotype. In cultured vascular smooth muscle cells, stimulation of AT 1receptors causes growth and hypertrophy. 32, 33 Thus, the development of vascular hypertrophy in mice that lack this putative growth factor receptor was unexpected. Dysregulated expression of PDGF and TGF-β has been demonstrated in these abnormal vessels. 22 However, the precise pathogenesis of these vascular lesions is not known.
Atrophy of the inner medulla is another characteristic feature of the phenotype of AT 1A / AT 1B 'double knockout' mice, 15, 31 as well as other lines of mice that are unable to produce Ang II. 22, 34 This lesion, which resembles hydronephrosis, becomes progressively worse with age and is associated S11 with a marked impairment of urinary concentration. 15, 34 Miyazaki and associates have suggested that diminished peristalsis of the renal pelvis and ureter might contribute to this abnormality. 35 Because the size and length of the renal papilla in mammals generally correlates with urinary concentrating capacity, 36 progressive atrophy of the renal papilla almost certainly contributes to the concentrating defect observed in these mice. However, mice with AT 1A -deficiency alone or wildtype mice treated with AIIAs also have significant urinary concentrating defects, despite an anatomically-normal renal papilla, suggesting a direct role of AT 1A -receptors in regulating water excretion. 37 AT 1 -receptors and regulation of blood pressure Consistent with the well-established role of the RAAS in BP regulation, several RAAS gene disruptions were associated with low resting BP. For example, the complete absence of angiotensinogen 21 or ACE 34,38 caused a reduction in systolic BP of approximately 20 mmHg, measured by tail-cuff in conscious animals. BP in AT 1A -receptor-deficient mice was reduced to a similar extent as the Agt -/and Ace -/-mice, 24 suggesting that most of the effect of Ang II to regulate resting BP in mice is mediated through the AT 1A -receptor.
Using receptor autoradiography, we found that AT 1 -specific binding was virtually absent in the kidneys of Agtr1a -/-mice 24 confirming the position of the AT 1A -receptor as the major renal AT 1 -receptor isoform. In Agtr1a +/-heterozygote mice,AT 1 -specific binding was also reduced, by approximately 50%. Thus, the absence of a single Agtr1a allele resulted in a substantial reduction in AT 1 -specific binding, that was not compensated through other regulatory mechanisms. This altered density of receptor expression causes significant reductions in BP. 24 Resting BP, measured by tail-cuff manometry, was significantly reduced in Agtr1a +/-mice (101±2 mmHg) compared with controls (113±2 mmHg; p=0.011). BP was even lower in the Agtr1a -/-mice (89±4 mmHg; p<0.0001 vs. wild-type). A similar hierarchy of BP among the genotypes was seen when mean arterial pressure was measured directly in conscious mice using intra-arterial catheters. Thus, there is a direct relationship between BP and expression of the Agtr1a gene. Even a partial reduction in expression has a demonstrable effect, and this effect is seen in animals with all of their homeostatic mechanisms otherwise intact. These studies suggest that variants of the human AT 1A -receptor gene that alter its level of expression might likewise affect BP. In this regard, associations between polymorphisms in the human Agtr1a gene and hypertension have been reported. 39, 40 BP and physiological responses to Ang II are normal in AT 1B -deficient mice. 15, 30 However, a contribution of AT 1B -receptors to vascular responses and regulation of BP was demonstrated in experiments using Agtr1a -/-mice. 41 In these studies, Agtr1a -/-mice were pretreated with enalapril to reduce endogenous Ang II production. This uncovered a pressor response to exogenous infu-sion of Ang II. This pressor response was blocked by administration of the AT 1 -receptor antagonist candesartan but was unaffected by sympatholytic agents, suggesting that it was a direct effect of AT 1B -receptor stimulation. In addition, chronic administration of an AT 1 -receptor antagonist to AT 1A -deficient mice caused further lowering of their systemic BP. These findings suggest that, in the absence of AT 1A -receptors,AT 1B -receptors contribute to the regulation of resting BP.
The major difference between the acute effects of Ang II in Agtr1a -/-and +/+ mice was in the magnitude of the pressor response. 41 In wildtype mice, the peak increase in BP following infusion of Ang II was significantly greater at each dose of Ang II tested and the overall slope of the dose response curve was higher than in the Agtr1a -/-group. However, the shape of the pressure curves following Ang II injection was qualitatively similar in the two groups. Accordingly, the simplest explanation for these results is that the differences in responses between Agtr1a +/+ and -/-mice are likely to be related to differences in receptor number, because AT 1A -receptors are much more highly expressed in vascular tissues than AT 1B -receptors. 10, 42 The similarity in the character of the pressor responses suggests that the signalling-effector mechanisms coupled to vasoconstriction are likely to be quite similar in AT 1Band AT 1B -receptors. This hypothesis was further supported by the observation that stimulation of AT 1B -receptors by Ang II in aortic smooth muscle cells derived from Agtr1a -/-mice induces a brisk increase in intracellular calcium that is similar to that elicited by Ang II in wild-type cells. 43 Finally, acute infusions of Ang II had no discernable effect on BP in double homozygous Agtr1a -/-Agtr1b -/mice 15 that had been pretreated with an ACE-I, confirming the conclusion that the vasoconstrictor actions of Ang II in Agtr1a -/-mice are mediated by AT 1B -receptors. Furthermore, the absence of any haemodynamic response to Ang II in Agtr1a -/-Agtr1b -/-mice suggests that no other Ang II receptors have acute vasoactive functions.
To determine the contribution of endogenous Ang II to maintaining BP in animals completely lacking AT 1 -receptors, Agtr1a -/-Agtr1b -/-and wild-type mice were treated with the ACE-I, enalapril, for two weeks while systolic BP was monitored. 15 The ACE-I significantly lowered BP in the wild-type animals. In contrast, ACE-I had a paradoxical effect on BP in the mice lacking both AT 1A -and AT 1B -receptors. In these mice, administration of the ACE-I caused a significant increase in BP from 87±3 to 94±3 mmHg (p=0.03).This paradoxical effect of ACE-I to increase BP in Agtr1a -/-Agtr1b -/-mice may result from interruption of AT 2 -receptor signalling. This would be consistent with studies suggesting that AT 2 -receptors oppose the actions of AT 1 -receptors on BP 13 and other cellular functions. 14 Since Ang II infusions do not acutely alter BP in Agtr1a -/-Agtr1b -/-mice, 15 we speculate AT 2 -receptors may regulate BP by modulating renal sodium excretion rather than by affecting vascular tone.
A role for AT 1B -receptors in regulation of drinking behaviour
Ang II has potent dipsogenic effects that are believed to stimulate drinking behaviour during states of volume depletion. 2 Pharmacological studies had suggested that these actions were mediated by AT 1 -receptors. 3 The AT 1A -receptor is the predominant AT 1 -receptor isoform in the brain [44] [45] [46] with prominent expression in major forebrain cardiovascular and fluid regulatory centres. 46 AT 1Breceptors are also expressed in the brain and in the anterior pituitary gland. [44] [45] [46] However, the relative contributions of these AT 1 -receptor subtypes to central Ang II responses such as stimulation of drinking cannot be discriminated with pharmacological inhibitors. To address this issue, Davisson compared drinking responses in conscious Agtr1a -/-and Agtr1b -/-mice following intra-cerebroventricular (ICV) injections of Ang II. 47 In wildtype mice, ICV injection of Ang II elicited brisk and pronounced drinking responses. This effect was reduced slightly in the AT 1A -receptor-deficient animals. In the mice lacking AT 1B -receptors, drinking responses were almost completely abolished, suggesting an essential function of AT 1B -receptors in regulating drinking responses to Ang II.
Because there does not appear to be a human homologue of the AT 1B -receptor, these findings suggest that the separate functions mediated by brain AT 1A and AT 1B sub-type receptors in lower mammals have been merged and are provided by a AT 1 -single receptor in humans. If so, it is interesting that the global actions of AT 1 -receptors in the CNS are very similar in humans and rodents. Alternatively, there may be an, as yet, unidentified angiotensin receptor in human brain that plays a role in body fluid regulation. Nonetheless, this divergence of function between AT 1A -and AT 1Breceptors in brain provides a scenario to identify the more distal signals involved in drinking responses stimulated by Ang II.
AT 1 -receptors and sodium homeostasis
Ang II regulates renal sodium handling through three distinct mechanisms: effects on renal haemodynamics, 48 direct stimulation of sodium reabsorption by renal tubular epithelial cells 49, 50 and stimulation of aldosterone production by the adrenal glands. 51 To examine the role of AT 1A -receptors in regulating sodium balance during changes in dietary sodium intake, we measured systolic BP responses in AT 1A -receptor-deficient and wild-type mice while dietary sodium content was systematically altered. 52 As shown in Figure 2 , the absence of AT 1A -receptors causes sodium-dependent BP changes or 'sodium sensitivity'.
To determine whether these changes in BP were accompanied by detectable alterations in sodium excretion, balance studies were performed using metabolic cages designed to house individual mice. 52 During high-salt feeding, urinary sodium excretion increased significantly and to similar levels in the Agtr1a +/+ and -/-mice. On the low-salt diet, urinary sodium excretion fell precipitously in both the Agtr1a +/+ and -/-groups, but remained wild-type mice (black square). Data are presented as the mean±SEM. On a control (0.4% NaCl) diet (C1 or C2), systolic blood pressures were significantly lower in Agtr1a -/-than wild-type mice (79±4 vs. 102±4 mmHg; p<0.005). In wild-type mice, increasing or decreasing dietary sodium content within the range tested had no effect on blood pressure. In contrast, when Agtr1a -/-mice were fed a high salt (6% NaCl) (HS) diet, their systolic blood pressures increased by 15 mmHg (from 79±4 to 94±4 mmHg; p<0.006).When the Control Diet was re-instituted, blood pressures in the Agtr1a -/-mice returned to their previous level.The low blood pressures of Agtr1a -/-mice decreased further when they were fed a low-salt (<0.02% NaCl) diet (LS) (82±3 to 69±3 mmHg; p<0.034). REVIEW significantly higher in the Agtr1a -/-mice than controls. As a consequence, as shown in Figure 3A , during seven days of sodium deprivation, cumulative sodium balance remained neutral in the wild-type mice (-0.003±0.022 mEq) but became significantly negative in the Agtr1a -/-mice (-0.77±0.18 mEq; mean±SEM, p=0.02 vs. Agtr1a +/+). We also compared the effects of altering sodium intake on urinary aldosterone excretion. 52 As shown in Figure 3B , on the high-salt diet, urinary aldosterone excretion was equivalently suppressed in both groups. The low sodium diets caused significant stimulation of aldosterone excretion in both groups, and the levels of aldosterone excretion were equivalent in the Agtr1a -/and +/+ groups. Ang II is a major regulator of aldosterone release, and this action is mediated by AT 1 -receptors in the adrenal zona glomerulosa. 3 Nonetheless, despite the absence of the major murine AT 1 -receptor, Agtr1a -/-mice increased aldosterone levels appropriately in response to sodium depletion. The preservation of aldosterone regulation in response to alterations in dietary sodium in the Agtr1a -/-mice may be explained by residual AT 1B -receptors expressed in the adrenal glands of rodents. 10, 42 Alternatively, Okubo and associates have found that aldosterone responses are also intact in angiotensinogendeficient mice, 53 suggesting that substantive regulation of aldosterone release can occur in the absence of a functional RAAS.
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Our studies indicate that low BP in Agtr1a -/mice is caused by sodium and extra-cellular volume depletion and that BP can be restored toward normal with dietary sodium loading. Since aldosterone responses are preserved in these animals, their sodium-dependent BP changes suggest a critical role for direct effects of AT 1A -receptors in the kidney to modulate sodium handling. These studies also imply that inhibition of renal AT 1 -receptors by AT 1 -receptor blockers probably contributes significantly to their antihypertensive actions.
